Latest Gannet BioChem News & Updates

See the latest news and media coverage for Gannet BioChem. We track all announcements, press releases, and industry mentions in real time, all in one place.

Gannet BioChem

Specialized CDMO for polymer science in therapeutics

gannetbiochem.com

Headquarters: Huntsville, United States
Founded year: 1998
Company type: Private company
Number of employees: 100–200
Industry: Specialty Chemicals

Last updated October 27

Latest news about Gannet BioChem

In short: Gannet BioChem acquired Laysan Bio, expanding its activated-polymer and bioconjugation capabilities.

Company announcements

October 27 Gannet BioChem

Gannet BioChem signs agreement with Re-Vana Therapeutics

The partnership combines Re-Vana’s ophthalmic tech with Gannet’s cGMP manufacturing for sustained-release drug delivery platforms like EyeLief.

January 22 Gannet BioChem

Gannet BioChem acquires Laysan Bio

The acquisition expands activated polymer and bioconjugation capabilities, enhancing support from early development to GMP manufacturing. It aligns with Gannet BioChem's strategy.

March 11, 2025 Gannet BioChem

Gannet BioChem appoints Nicholas Shackley as CEO

The company announces Chris Edwards as CFO and Dr. Tony Sander as COO following acquisition by Ampersand Capital Partners. Leaders bring extensive industry experience.

December 3, 2024 Gannet BioChem

Ampersand Capital acquires PEG reagent business, launches Gannet BioChem

The private equity firm acquired the business from Nektar Therapeutics. Gannet BioChem will operate as an independent CDMO in Huntsville, Alabama.

Media coverage

October 26 The Globe and Mail

Gannet BioChem and Re-Vana Therapeutics Enter Development and cGMP Supply Agreement to Support Ophthalmic Drug Delivery Program

Gannet BioChem, a specialized contract development and manufacturing organization (CDMO) focused on activated polymers and bioconjugation, and Re-Vana Therapeutics, a biotechnology company developing sustained-release therapeutics...

June 30 Markets Insider

Gannet BioChem and Serina Therapeutics Enter Development Partnership Supporting SER-252 Program

Gannet BioChem, a leading life sciences manufacturing company, today announced a development partnership with Serina Therapeutics, Inc. (NYSE American: SER), a clinical-stage biotechnology company advancing...

March 11, 2025 WOOD TV

Gannet BioChem Names Nicholas Shackley as Chief Executive Officer, Announces Leadership Team Expansion

HUNTSVILLE, Ala., March 11, 2025 /PRNewswire/ -- Gannet BioChem, a leading specialty chemical Contract Development and Manufacturing Organization (CDMO), today announced the appointment of key...

February 27, 2025 Ozarks First

Ampersand Capital Partners Completes Acquisition of Nektar Therapeutics' PEG Reagent Manufacturing Business, Launching Newly Branded Gannet BioChem

BOSTON and HUNTSVILLE, Ala., Dec. 2, 2024 /PRNewswire/ -- Ampersand Capital Partners, a private equity firm specializing in growth equity investments in the life sciences...

Never miss news about Gannet BioChem

Track Gannet BioChem and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Trending companies

Discover what's making headlines across other trending companies.